人自然殺傷性細胞NK92

細胞名稱

人自然殺傷性細胞NK92

貨物編碼

BFN608006464

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研           3類

培養體系

The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.

培養溫度

37℃

二氧化碳濃度

5%

簡介

人自然殺傷性細胞NK92是從一位患有急進性非霍奇金淋巴瘤的50歲白人男性外周血單核細胞衍生來的一株白細胞介素-2依賴型NK細胞株。NK-92MI是轉染得到的源自NK-92的IL-2非依賴的NK細胞株，親本細胞通過微粒體基因轉化法用逆轉錄病毒MFG-hIL-2載體攜帶的人IL-2cDNA進行轉化。可能由于載體整合到基因組DNA中，轉化是穩定的。這株細胞對很多惡性細胞有細胞毒性；鉻釋放試驗顯示它能殺死K562和Daudi細胞。NK-92細胞有以下特征：CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -。另本庫保藏有NK92MI細胞。二者均引種自ATCC。

補充

NK92細胞培養時，會有零星聚團現象，此時吹打散開即可。處于平臺期的細胞，會有少量呈現略不規則的圓形，此為正常現象。血清建議使用BCK北美胎牛血清（貨號BCK041）與BCK馬血清（貨號BCK045)。

注釋

Part of: LL-100 blood cancer cell line panel.

Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also bBeing developed for cellular adoptive immunotherapy for cancers and viral infections.

Characteristics: IL2 dependent.

Characteristics: Does not express FCGR3A/CD16.

Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ).

Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: Transcriptome analysis.

Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.

Derived from sampling site: Peripheral blood.

STR信息

Amelogenin        X,Y

CSF1PO        11,12

D5S818        12,13

D7S820        10,11

D13S317        9,12

D16S539        11,12

TH01        6,9.3

TPOX        8

vWA        18 (ATCC)

16,18 (DSMZ)

參考文獻

PubMed=25586472; DOI=10.1038/ncomms7025

Kucuk C., Jiang B., Hu X., Zhang W., Chan J.K.C., Xiao W., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W., Cornish A., Gong Q., Yang Q., Sun H., d'Amore F., Leppa S., Liu W., Fu K., de Leval L., McKeithan T., Chan W.C.

Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.

Nat. Commun. 6:6025-6025(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x

Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2

Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.

Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.

J. Immunother. Cancer 7:138-138(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)